With a budget of nearly
“Our Fionet Platform is a valuable tool against many outbreaks such as malaria and COVID-19,” said Dr
The DRC is an important country in central
Fionet Mobile Devices support frontline testing, and continuously capture and transmit comprehensive data to a centralized aggregation point. In real time, Fionet Portals allow off-site supervisors to track and direct frontline action, displaying accurate epidemiological information and providing actionable insights. A recently published medical research paper demonstrated that Fionet’s quality was comparable to expert lab technicians6.
Prior to the outbreak of the COVID-19 pandemic, Fionet was successfully used to test and track over one million patients in remote settings around the world for infectious diseases including malaria, HIV and dengue fever.
The Fionet Platform was most recently deployed for rapid COVID-19 testing in Canada’s largest international airport. Ongoing testing engagements include COVID-19 rapid testing with
The Company announces that it has granted an aggregate of 2,500,000 options to purchase common shares of the Company at
SUBSCRIBE: For more information on Relay or to subscribe to the Company’s mail list visit: https://www.relaymedical.com/news
About
About Fionet
The Fionet Platform is an end-to-end, rapid testing and tracking solution for community-based or decentralized settings. Combining a fast, handheld point-of-need device connected in real time to cloud data services, the Fionet Platform handles scheduling and registration via phone app for at home, on-site check-in and rapid on-the-spot universal antigen testing. The platform allows for data integration with other testing methods and devices, providing result notification for patient and public health authorities as appropriate, and anonymized data and statistics for dashboards for authorized stakeholders.
Website: www.fionetrapidresponse.com
About
Relay Medical is a technology innovator headquartered in
Website: www.relaymedical.com
Contact:
Destine Lee
Office. 647-872-9982
TF. 1-844-247-6633
Media Inquiries: media@relaymedical.com
Investor Relations: investor.relations@relaymedical.com
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com
___________________
1 https://www.usaid.gov/
2 https://www.usaid.gov/sites/default/files/documents/1881/FY2021_Budget_FactSheet.pdf
3
4 https://www.who.int/news-room/fact-sheets/detail/malaria
5 https://www.sciencedirect.com/science/article/pii/S2214180418300412
6 BMC Infectious Diseases, 2020 https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-4932-0
Source:
2021 GlobeNewswire, Inc., source